Trade Secrets: The ‘Reasonable Steps’ Requirement 19/08/2015 by Intellectual Property Watch Leave a Comment Trade secret theft is a top risk for companies today. When the worst does happen and trade secrets are compromised, companies must prove that reasonable steps have been taken to protect a company’s crown jewels. But determining what “reasonable steps” are can be challenging. Governments have been vague about the term’s definition; and laws and legislation continue to evolve on this issue. However, court actions do provide insight on the ‘reasonable steps requirement’ and point to the need for companies to embed trade secret protection into business operations to qualify as legal protection, writes Pamela Passman.
Five Reasons Why TPP Countries Should Unite To Oppose The US Pharmaceutical IP Agenda 18/08/2015 by Intellectual Property Watch 3 Comments Failure to reach agreement over expanded intellectual property (IP) protections for medicines has proven to be a stumbling block to completion of the 12-country Trans Pacific Partnership negotiations. As expected, the US is continuing to pressure negotiating partners to adopt broader and longer monopoly protections for medicines. But the risks for their health systems are very high – and will be much higher if they don’t stick together in rejecting the US demands.
IP-Watch Seeks Part-Time Fundraising/Outreach Expert 31/07/2015 by Intellectual Property Watch Leave a Comment Intellectual Property Watch is seeking a dynamic person to help expand our fundraising and outreach activities. [Position closed]
The TPP’s Reckless Proposals For Damages Will Have Negative Impact On Future Reform Of IPR Regimes 28/07/2015 by Intellectual Property Watch 13 Comments James Love writes: This week negotiators from a dozen countries are meeting to finalize the rules for the Trans Pacific Partnership (TPP) trade agreement. When or if concluded, this massive regional trade agreement will set new standards for the grant of property rights in knowledge, and the enforcement of those rights. The TPP chapter on intellectual property covers all intellectual property types included in Part II of the WTO’s TRIPS agreement, plus some others, including not only patents, copyrights and trademarks, but also “undisclosed information”, test data for the registration of drugs, industrial designs, layout-designs of integrated circuits. The rules in the TPP are intended by the United States to become global norms, effectively replacing TRIPS. While there are plenty of issues in the TPP IP Chapter, this note only addresses one set of issues — those relating to the remedies for the infringement of intellectual property rights. The remedies include such topics as injunctions, damages, and the seizure or destruction of infringing goods.
Decision Time On Biologics Exclusivity: Eight Years Is No Compromise 27/07/2015 by Intellectual Property Watch 14 Comments Burcu Kilic and Courtney Pine write: As the Trans-Pacific Partnership (TPP) negotiations approach their endgame, biologics exclusivity is still considered “one of the most difficult outstanding issues in the negotiation.”[2] Pharmaceutical companies seek longer data and marketing exclusivities to further delay market entry of cost-saving biosimilar drugs. Data exclusivity prevents follow-on pharmaceutical developers from relying on originators’ test data submitted for marketing approval while seeking such approval for its own product. The World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) requires some protection against unfair competition for this sort of data, but it does not require countries to adopt rules conveying exclusive rights over it in the same way as it does regarding patents.[3] Currently, the US provides 12 years of exclusivity for new biological products under the Biologics Price Competition and Innovation Act (BPCIA).[4] The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law, The Patient Protection and Affordable Care Act. A robust debate over what would be an appropriate exclusivity period, if any, was overshadowed by other controversial aspects of the bill commonly referred to as Obamacare.
WHO Negotiations To Continue On Non-State Actors 21/07/2015 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment Third World Network reports: New Delhi, 20 July (K M Gopakumar) – Member States of the World Health Organization have decided to continue the negotiations on a Framework of Engagement with Non-State Actors (FENSA) as several key issues remain unresolved.
Defendants, Non-Profits, Defensive Aggregators And Hedge Funds: Common And Less Common Uses Of Inter Partes Review 16/07/2015 by Intellectual Property Watch Leave a Comment Inter partes review (“IPR”) proceedings were originally intended to allow defendants in patent infringement lawsuits to invalidate questionable patents cheaply and quickly. But these proceedings increasingly are being used by parties that are not defendants in active litigation matters at all, write Rich Hung and Alex Hadduck.
Learning From Ebola 14/07/2015 by Intellectual Property Watch 1 Comment In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding. Because he was initially believed to have malaria, Lokela was given quinine, but his symptoms got worse and he soon died. Shortly afterwards, those who had been in contact with Lokela also died. … Almost four decades later, there is still no cure for Ebola, despite the fact that drug development on average takes about a third of this time frame, write William Fisher and Quentin Palfrey.
3D Printing And Public Policy 09/07/2015 by Intellectual Property Watch 12 Comments John Hornick writes: Although legal principles apply to 3D printing the same as they apply to any other technology, 3D printing has the unique potential to upset the legal status quo. It is the potential scale of 3D printing that may have profound effects on the law. 3D printing cuts across many areas of law, most types of technology, and almost all types of products. Eventually, anyone may be able to make almost anything. No one else will know they made it or be able to control it, which I call 3D printing away from control.
US Federal Judge Orders Cancellation Of Redskins’ Football Team Trademark Registrations 09/07/2015 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment The Washington Post reports: The Washington Redskins – an American football team – lost their biggest legal and public relations battle yet in the war over their name after a federal judge on Wednesday ordered the cancellation of the NFL team’s federal trademark registrations, opposed for decades by Native American activists who call the moniker disparaging.